Product References
The Effects of Protein Phosphatase 2A Activation with Novel Tricyclic Sulfonamides on Hepatoblastoma.
Journal of pediatric surgery
Bownes LV,Julson JR,Quinn CH,Hutchins SC,Erwin MH,Markert HR,Stewart JE,Mroczek-Musulman E,Aye J,Yoon KJ,Ohlmeyer M,Beierle EA
Thu Jun 01 00:00:00 EDT 2023
Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma.
Cancers
Bownes LV,Marayati R,Quinn CH,Beierle AM,Hutchins SC,Julson JR,Erwin MH,Stewart JE,Mroczek-Musulman E,Ohlmeyer M,Aye JM,Yoon KJ,Beierle EA
Wed Apr 13 00:00:00 EDT 2022
MicroRNA-1915-3p inhibits cell migration and invasion by targeting SET in non-small-cell lung cancer.
BMC cancer
Pan H,Pan Z,Guo F,Meng F,Zu L,Fan Y,Li Y,Li M,Du X,Zhang X,Shao Y,Wei M,Li X,Zhou Q
Sat Nov 13 00:00:00 EST 2021
MicroRNA-1915-3p inhibits cell migration and invasion by targeting SET in non-small-cell lung cancer.
BMC cancer
Pan H,Pan Z,Guo F,Meng F,Zu L,Fan Y,Li Y,Li M,Du X,Zhang X,Shao Y,Wei M,Li X,Zhou Q
Sat Nov 13 00:00:00 EST 2021
Selective Peptidomimetic Inhibitors of NTMT1/2: Rational Design, Synthesis, Characterization, and Crystallographic Studies.
Journal of medicinal chemistry
Mackie BD,Chen D,Dong G,Dong C,Parker H,Schaner Tooley CE,Noinaj N,Min J,Huang R
Thu Sep 10 00:00:00 EDT 2020
Overexpression of SET oncoprotein is associated with tumor progression and poor prognosis in human gastric cancer.
Oncology reports
Yuan X,Zhang T,Zheng X,Zhang Y,Feng T,Liu P,Sun Z,Qin S,Liu X,Zhang L,Song J,Liu Y
Fri Sep 01 00:00:00 EDT 2017
Overexpression of SET oncoprotein is associated with tumor progression and poor prognosis in human gastric cancer.
Oncology reports
Yuan X,Zhang T,Zheng X,Zhang Y,Feng T,Liu P,Sun Z,Qin S,Liu X,Zhang L,Song J,Liu Y
Fri Sep 01 00:00:00 EDT 2017
Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Oncotarget
Liu H,Gu Y,Wang H,Yin J,Zheng G,Zhang Z,Lu M,Wang C,He Z
Sat Jun 20 00:00:00 EDT 2015
Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Oncotarget
Liu H,Gu Y,Wang H,Yin J,Zheng G,Zhang Z,Lu M,Wang C,He Z
Sat Jun 20 00:00:00 EDT 2015
SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell.
Cellular signalling
Liu H,Gu Y,Yin J,Zheng G,Wang C,Zhang Z,Deng M,Liu J,Jia X,He Z
Mon Dec 01 00:00:00 EST 2014
SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell.
Cellular signalling
Liu H,Gu Y,Yin J,Zheng G,Wang C,Zhang Z,Deng M,Liu J,Jia X,He Z
Mon Dec 01 00:00:00 EST 2014
Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.
Journal of cellular biochemistry
Yang Y,Huang Q,Lu Y,Li X,Huang S
Sun Apr 01 00:00:00 EDT 2012
Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.
Journal of cellular biochemistry
Yang Y,Huang Q,Lu Y,Li X,Huang S
Sun Apr 01 00:00:00 EDT 2012